What the current evidence shows
Inner Balance, LLC operates the nonclinical platform. Its privacy notice identifies Inner Balance Health, PLLC as a practice and describes Inner Balance, LLC as a business associate. The terms say contracted clinicians exercise independent medical judgment and can decline care or a prescription.
Sarah Maria Daccarett, MD is presented as founder and chief executive. The federal NPI registry returns an active exact-name physician record at Inner Balance's Boise address, with Clinical Pathology as the primary taxonomy. The Virginia Board of Medicine also lists a current active physician license at that address. These records verify identity and licensure examples, not every marketing credential or a fifty-state license claim.
The care path begins with a product-specific questionnaire. A licensed clinician reviews symptoms, history, medications, and treatment fit. Current product pages describe an asynchronous decision without a routine required visit, while the terms permit messaging, audio, video, and requests for outside tests or records. Payment does not guarantee a prescription.
Oestra is a compounded daily vaginal cream containing 3 mg estradiol and 100 mg micronized progesterone per pump. Another current page describes the same formula as 0.3 percent estradiol and 10 percent progesterone. The site markets systemic effects, but the finished compounded product is not FDA approved and its categorical safety and outcome claims are not independently established by ingredient approval.
Oestra costs $199 per month for the first six months and $99.50 per month afterward. A 90-day supply is replenished every 90 days while billing occurs monthly. Shipping and continuing clinical follow-up are included. The page says dose adjustments may add cost, but it does not publish a schedule for those charges.
Oestra's first and later prices are lifecycle phases, not comparable plan options, so they are not averaged. The compact card shows the $199 introductory monthly charge, and the notes retain the $99.50 maintenance amount and six-month transition.
Libida is a compounded sublingual tablet containing 1 mg bremelanotide and 20 IU oxytocin. Inner Balance says it is used on demand and should not be taken more than once in 72 hours. The site markets it across premenopausal and postmenopausal life stages, subject to clinical review.
FDA approval for bremelanotide does not transfer to Libida. The approved Vyleesi product is a 1.75 mg subcutaneous injection for acquired generalized hypoactive sexual desire disorder in selected premenopausal women. The label says it is not indicated for postmenopausal women or sexual-performance enhancement. Libida uses a different dose, route, dosage form, and an added active ingredient.
Libida's product page says from $99.70 per month. Public articles list $249 for 10 tablets one time, $199 for 10 monthly, and $299 for 30 every three months. The two-month offer conflicts with itself by displaying both $249 and $279. No combined average is used until that charge is resolved.
Inner Balance NAD+ is a compounded 200 mg sublingual tablet taken daily and kept refrigerated. Subscription prices are $199 for 30 days, $379 for 60 days, or $549 for 90 days. The effective rates of $199, $189.50, and $183 average to Avg. $191/mo. One-time totals are separate and are not blended into that subscription average.
The NAD+ product is prescription-only and not FDA approved. Current pages connect the molecule's biochemical role to energy, repair, focus, stress resilience, and healthy aging. Those promotional outcomes are not treated as established patient benefits for the exact compounded sublingual product.
BodyMatched combines estriol 0.3 percent, tretinoin 0.01 percent, and niacinamide 0.01 percent in a compounded topical cream. An optional version adds finasteride 0.25 percent for $20 per month. The product is kept under its ingredient combination rather than split into separate tretinoin or finasteride medication cards.
The BodyMatched help center lists $129 monthly, $199 every two months, $239 every three months, or $169 one time. The product page says from $83 per month, but $239 divided by three is $79.67. Because the current sources disagree, the card uses the unambiguous $129 monthly plan and does not calculate a blended average.
All four prescriptions are compounded combinations or route variants without exact reusable AllyRx catalog matches. They remain visible under their real active ingredients and provider product labels, but they do not enter medication-level price benchmarks. That avoids treating Oestra as estradiol alone, Libida as bremelanotide injection, NAD+ sublingual tablets as NAD+ injections, or BodyMatched as tretinoin alone.
The site says treatments are prepared through licensed U.S. compounding pharmacies and displays NABP, PCAB, LegitScript, 503A, sourcing, and testing badges. It does not consistently name the pharmacy, publish accreditation records, or tie a certificate to the prescription a patient will receive. A BodyMatched help article names Strive Pharmacy only in a disclaimer, which is not enough to assign Strive to every product.
FDA does not approve compounded drugs before marketing or verify their safety, effectiveness, or quality. State boards primarily oversee conventional 503A pharmacies, and 503A status does not itself establish FDA approval of a pharmacy or finished prescription. The pharmacy label remains the authoritative source for dispenser, ingredients, concentration, storage, and beyond-use date.
The general FAQ says Oestra does not require laboratory work to start and describes symptom-based review. The terms still allow a clinician to order laboratory, imaging, or diagnostic testing outside the practice, potentially at additional cost. The exact monitoring plan should come from the treating clinician.
Oestra ships as a 90-day supply and is billed monthly. The provider says a prescription is compounded and shipped within three to five business days after approval, then most U.S. deliveries take another three to five business days. Tracking is sent by SMS. Other product pages say shipping is free and fast but publish fewer product-specific handling and replacement details.
Subscriptions may bill monthly, every two months, or every three months, and one-time prescriptions are charged upfront. A patient can cancel through the secure account portal. If three months of Oestra were dispensed before all three monthly payments were collected, the terms say a reactivation fee may apply later.
Cancellation and refund requests are separate. Oestra refunds require a request within six months of the original order and within 14 days after cancellation. BodyMatched's 30-day guarantee applies only to an initial three-month subscription. Libida, NAD+, supplements, laboratory tests, and third-party services are excluded, and only one refund is allowed per customer.
The terms honor pharmacy choice but allow Inner Balance to continue charging its service fee when a patient routes the prescription elsewhere. The patient then pays the outside pharmacy separately. That option can produce two charges and should be confirmed before requesting a transfer.
Public support is centered on the secure account portal. Patients can request refills, contact support, message a provider, cancel, and submit a refund request there. The product pages promise continuing clinical access, but no working public contact form, phone number, email address, operating hours, or response-time target was found. Emergencies are directed to 911.
Inner Balance does not accept commercial insurance, Medicare, or Medicaid. Current pages say HSA and FSA cards are accepted at checkout, although eligibility depends on the account and expense. Patients are responsible for outside services and should not assume reimbursement.
State and age eligibility are not resolved cleanly. Marketing pages claim service across all states and a general FAQ says Oestra may be available from age 21, while the privacy policy says services are limited to people age 35 or older. The terms say some services may be unavailable by state. Product-specific intake and clinician licensure should control.
The privacy notice names Inner Balance Health, PLLC and describes protected-health-information uses for treatment, payment, operations, pharmacy, laboratory, and electronic-health-record activities. The separate privacy policy also covers identity, payment, device, analytics, location, health, and program data and allows interest-based advertising and cross-site tracking.
The privacy and HIPAA text contains copied Calibrate references and sends an undefined-terms link to joincalibrate.com. The same policy says services are age 35 and older while the current clinical FAQ says age 21. These errors do not prove how data is handled, but they materially reduce confidence in policy maintenance.
The site displays internal ratings, patient counts, testimonials, outcome percentages, and claims involving thousands of women without a public collection method, moderation policy, protocol, or source record. AllyRx does not convert those figures into a user rating or represent them as independently verified outcomes.
The Katalys application is pending under offer 1505 with an internal discovery payout of $50 and EPC of $5.56. No tracking link or affiliate-compatible customer promotion is available in the current record. The unpublished CTA therefore uses the canonical Inner Balance domain without a discount line.
- Four prescription products are consolidated under their actual active ingredients, routes, and dosage forms.
- Three consistent NAD+ subscription terms produce a reproducible Avg. $191/mo figure.
- The platform, clinical practice, founder, clinician review, and compounded status are identifiable.
- Price, age, pharmacy, refund, clinical-copy, and legal-document conflicts require checkout and label verification.
